دورية أكاديمية
The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study.
العنوان: | The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. |
---|---|
المؤلفون: | NazimTurhal S; Department of Medical Oncology, Anadolu Medical Center, Istanbul, Turkey., Dogan M; Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey. mutludogan1@yahoo.com., Esendagli G; Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey., Artac M; Department of Medical Oncology, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey., Korkmaz L; Department of Computer Engineering, Faculty of Engineering, Istinye University, Istanbul, Turkey., Coskun HS; Department of Medical Oncology, Akdeniz UniversityFaculty of Medicine, Antalya, Turkey., Goker E; Department of Medical Oncology, Ege UniversityFaculty of Medicine, Izmir, Turkey., PerranYumuk F; Department of Medical Oncology, Marmara UniversityFaculty of Medicine, Istanbul, Turkey., Bilgetekin I; Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey., Kose F; Department of Medical Oncology, Faculty of Medicine, Baskent University, Adana, Turkey., Uncu D; Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey., Kavgaci H; Department of Medical Oncology, Faculty of Medicine, Karadeniz University, Trabzon, Turkey., Akyol G; Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey., Ozet A; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey., Yagci T; Department of Molecular Biology and Genetics, Faculty of Basic Sciences, Gebze Technical University, Kocaeli, Turkey. |
المصدر: | Journal of gastrointestinal cancer [J Gastrointest Cancer] 2022 Jun; Vol. 53 (2), pp. 356-362. Date of Electronic Publication: 2021 Mar 03. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2010- : New York : Springer Science+Business Media Original Publication: New York, NY : Humana Press |
مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/pathology , Receptors, Virus*/genetics, Biomarkers, Tumor ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Turkey |
مستخلص: | Purpose: Plexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced stage. We recently documented that Plexin C1 was overexpressed in HCC. We aimed to evaluate the prognostic significance of Plexin C1 overexpression in HCC in the present study. Methods: Plexin C1 overexpression was evaluated immunohistochemically on paraffin-embedded blocks of the HCC patients. Plexin C1 immunohistochemical staining was scored. Plexin C1 overexpression staining intensity and prevalence were used for plexin scale staining evaluation and plexin scores were estimated according this staining scale. Plexin C1 score and its association with survival and clinicopathological features was assessed. Results: Sixty-seven HCC patients with adequate tissue for pathological evaluation were included. Median age was 63 years with male predominance (male to female ratio was 4.75 (n 57/12). Well-differentiated HCC (53.7%) patients had higher plexin C1 overexpression (p < 0.05). Median OS was 22.1 months. Patients with lower plexin C1 score (< 12) had shorter OS (17.5 vs 30.1 months, p = 0.036). Neutrophil count, GGT, and PNR (platelet/neutrophil ratio) had prognostic significance (p = 0.047, p = 0.018, and p = 0.045). Conclusion: Plexin C1 overexpression is inversely correlated with grade in HCC. The patients with lower rate of Plexin C1 overexpression have worse survival outcome. It might be a prognostic factor in HCC. (© 2021. Springer Science+Business Media, LLC, part of Springer Nature.) |
References: | Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–1691. Odabas G, Cetin M, Turhal S, Baloglu H, Sayan AE, Yagci T. Plexin C1 marks liver cancer cells with epithelial phenotype and Is overexpressed in hepatocellular carcinoma. Can J Gastroenterol Hepatol (2018). 18 Sep19; 2018:4040787. https://doi.org/10.1155/2018/4040787 . eCollection 2018. Chan SL, Wong AM, Lee K, Wong N, Chan AKC. Personalized therapy for hepatocellular carcinoma: where are we now? Cancer Treat Rev. 2016;45:77–86. (PMID: 10.1016/j.ctrv.2016.02.008) Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73. (PMID: 10.1016/S0140-6736(18)30207-1) Heo YA, Syed YY. Regorafenib: a review in hepatocellular carcinoma. Drugs. 2018;78:951–8. (PMID: 10.1007/s40265-018-0932-4) Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63. (PMID: 10.1056/NEJMoa1717002) Yu L, Zhou Y, Cheng S, Rao Y. Plexin a-semaphorin-1 are verse signaling regulates photoreceptor axon guidance in Drosophila. J Neurosci. 2010;30:12151–6. (PMID: 10.1523/JNEUROSCI.1494-10.2010) Angelopoulou E, Piperi C. Emerging role of plexins signaling in glioma progression and therapy. Cancer Lett. 2018;414:81–7. (PMID: 10.1016/j.canlet.2017.11.010) Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression (2012). Cold Spring Harb Perspect Med 2: a006718. Rody A, Karn T, Ruckhaberle E, Hanker L, Metzler D, Muller V, et al. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers- results of a large scale microarray analysis. Eur J Cancer. 2009;45:405–13. (PMID: 10.1016/j.ejca.2008.10.016) Wong OG, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown RS, et al. Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci USA. 2007;104:19040–5. (PMID: 10.1073/pnas.0702544104) Stevens L, McClelland L, Fricke A, Williamson M, Kuo I, Scott G. Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. J Invest Dermatol. 2010;130:1636–45. (PMID: 10.1038/jid.2010.13) M. R. Comeau, R. Johnson, R. F. DuBose, Petersen M, Gearing P, VandenBos T, Park L, et al. A pox virüs encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 1998;8:473–482. Scott GA, McClelland LA, Fricke AF, Fender A. Plexin C1, a receptor for semaphorin7a, inactivates coflin and is a potential tumor suppressor for melanoma progression. J Investig Dermatol. 2009;129:954–63. (PMID: 10.1038/jid.2008.329) |
فهرسة مساهمة: | Keywords: Hcc; Hepatocellular carcinoma; Plexin |
المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Receptors, Virus) 0 (VESPR semaphorin receptor) |
تواريخ الأحداث: | Date Created: 20210303 Date Completed: 20220609 Latest Revision: 20220613 |
رمز التحديث: | 20231215 |
DOI: | 10.1007/s12029-021-00602-4 |
PMID: | 33656690 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!